000999.SZ
华润三九
SZSE · Healthcare · C 制造业 · CN
CNY 23.60
−2.24%Year over year
Reported trailing growth
- Revenue
- +21.0%
- EBITDA
- —
- EBIT
- +10.3%
- EPS
- -1.4%
- Free cash flow
- +12.4%
- Operating cash flow
- +21.6%
Forward estimates
Based on analyst estimates
- Revenue
- -0.8%
- EBITDA
- -17.4%
- EPS
- +20.7%
Three-year CAGR
- Revenue
- +20.5%
- EBITDA
- +21.0%
- EBIT
- +18.1%
- Net income
- +11.8%
- EPS
- -6.0%
- Free cash flow
- +27.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026